MaxCyte Inc. has announced a strategic partnership with Ori Biotech to enhance the efficiency, scalability, and productivity of cell therapy manufacturing. The collaboration integrates MaxCyte's ExPERT™ platform and Flow Electroporation® technology with Ori's IRO® platform, aiming to optimize gene-edited T cell yield and streamline manufacturing timelines. This joint effort underscores both companies' commitment to advancing cell and gene therapy solutions, ultimately accelerating the availability of transformative treatments for patients globally. The partnership will initially focus on evaluating CD19 CAR expression via CRISPR knock-in in activated T cells.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.